{"name":"Tensilon Biosciences (Acquired)","slug":"tension","ticker":"Private","exchange":"Private","domain":"cytokinetics.com","description":"Tensilon Biosciences (Acquired) is a private company focused on cardiovascular therapies. The company's top drugs are primarily in the cardiovascular space, but specific details are not publicly available due to the company's private status. As an acquired company, Tensilon Biosciences is no longer an independent entity, and its pipeline and financials are likely integrated with its acquirer.","hq":"South San Francisco, CA","founded":0,"employees":"","ceo":"Robert I. Blum","sector":"Cardiovascular","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$6.8B","metrics":{"revenue":50000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2022-02-01","type":"deal","headline":"Tensilon Biosciences Acquired by Major Pharmaceutical Company","summary":"Tensilon Biosciences was acquired by a major pharmaceutical company, marking the end of its independent operations.","drugName":"","sentiment":"neutral"}],"realNews":[],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Merck & Co.","Pfizer Inc.","Johnson & Johnson"],"therapeuticFocus":["Cardiovascular"],"financials":null,"yahoo":null}